Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Lucid Diagnostics Inc. on June 21, 2023. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. The filing details the election of directors and the approval of several corporate governance and capital structure amendments.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
The following material actions were approved by stockholders representing approximately 87.7% of shares outstanding:
- Director Elections: Ronald M. Sparks and James L. Cox, M.D. were re-elected as Class B directors for a term expiring at the 2025 annual meeting.
- Charter Amendment (Exculpation): The Certificate of Incorporation was amended to incorporate new Delaware law provisions regarding officer exculpation.
- Charter Amendment (Authorized Shares): The total number of authorized common shares was increased by 100,000,000, from 100,000,000 to 200,000,000 shares.
- Debt and Equity Issuance Approval: Stockholders approved the issuance of common stock upon conversion of the Senior Secured Convertible Note (March 2023 Note) and the Series A Convertible Preferred Stock sold in private offerings in March 2023, satisfying Nasdaq Listing Rule 5635.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. It references the Definitive Proxy Statement filed on May 1, 2023, for a fuller description of the amendments and the terms of the March 2023 Note and Series A Preferred Stock. No specific risks or contingencies are detailed within this specific 8-K text beyond the standard incorporation of referenced documents.
Investor Verification Checklist
- Verify the terms and conversion rates of the March 2023 Senior Secured Convertible Note and Series A Preferred Stock in the referenced March 2023 8-K filings.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific officer exculpation provisions.
- Confirm the impact of the 100 million share increase on potential future dilution.
- Check the Definitive Proxy Statement (Schedule 14A) for detailed voting breakdowns and director biographies.